Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Cash (2016 - 2025)

Cytokinetics (CYTK) has disclosed Change in Cash for 16 consecutive years, with $96.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash changed N/A to $96.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.3 million, a N/A change, with the full-year FY2025 number at $30.4 million, up 267.34% from a year prior.
  • Change in Cash was $96.5 million for Q4 2025 at Cytokinetics, up from -$21.2 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $96.5 million in Q4 2025 to a low of -$143.3 million in Q3 2024.
  • A 5-year average of $2.3 million and a median of $7.0 million in 2024 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: surged 1207.47% in 2023, then plummeted 561.32% in 2024.
  • Cytokinetics' Change in Cash stood at $22.1 million in 2021, then crashed by 276.69% to -$39.1 million in 2022, then soared by 134.14% to $13.3 million in 2023, then crashed by 1174.51% to -$143.3 million in 2024, then soared by 167.39% to $96.5 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Change in Cash are $96.5 million (Q4 2025), -$21.2 million (Q1 2025), and -$143.3 million (Q3 2024).